Daniel Lin is a distinguished scientist specializing in metabolism drug discovery at Genentech, where they currently lead innovative research efforts. They previously held the position of Director at 23andMe, focusing on cardiometabolic disease research from 2021 to 2023. Prior to that, Daniel contributed significantly in various roles at Amgen, including as a Senior Scientist, and gained foundational experience as a Scientist at Tularik from 2001 to 2004. Daniel holds a Bachelor of Arts in Molecular and Cell Biology from the University of California, Berkeley, and a Ph.D. in Biology from the Massachusetts Institute of Technology.
This person is not in the org chart
This person is not in any teams
This person is not in any offices